Drug intelligence / Profile preview

LR19123

Development stage: Preclinical
Lead developer: LG Chem
Modality: Small Molecules
Administration: Oral

Overview

LR19123 is an investigational oral drug candidate being developed by LG Chem for the treatment of type 2 diabetes. It is currently in the early stages of development, appearing in the company's metabolic disease pipeline. As a next-generation treatment, it is designed to address the needs of patients with type 2 diabetes, although its specific molecular target and mechanism of action have not been publicly detailed by the developer.

Targets

FFAR4 (Free fatty acid receptor 4)

Beyond the preview

Go deeper on LR19123.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LR19123.

Explore the full profile